Why consider PIFR (peak inspiratory
flow rate) in COPD patients?
Not an actual COPD patient.
With a DPI, why can PIFR be a concern?
DPIs rely on inspiratory flow
Low PIFR may lead to marked reductions in amount of fine particles/emitted dose reaching the lungs1-3
Low PIFR may also lead to marked reductions in lung deposition4
Low PIFR drives the majority of handling errors with DPIs5
PIFR >60 L/min may help to maximize drug delivery6-8
* Based on studies designed to measure inspiratory flow rates and drug delivery at different levels of resistance. These studies were not designed to evaluate efficacy and safety.
As with other inhaled beta2-agonists, BROVANA® (arformoterol tartrate) Inhalation Solution can produce paradoxical bronchospasm that may be life-threatening in COPD patients. If paradoxical bronchospasm occurs, BROVANA treatments should be discontinued immediately and alternative COPD therapy instituted.
BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some COPD patients as measured by increases in pulse rate,
blood pressure, and/or symptoms.
Twice-daily BROVANA® (arformoterol tartrate) may be the right fit
You are now leaving BROVANA.com. Sunovion is not responsible for the information contained in any of the linked sites.